Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Vertex’s CF ‘firepower’ to fund more deals, broader pipeline

Elizabeth S. Eaton, Staff Writer
August 1, 2019 12:00 AM UTC

Vertex unveiled a series of new programs Wednesday and provided a glimpse of how it plans to use the cash from its cystic fibrosis portfolio to fuel deals that will continue to propel the company into pain and rare diseases.

As Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) prepares for a potential 2020 launch of its triple combination CF therapy that can treat up to 90% of patients, Jeffrey Leiden will step down as president and CEO and become executive chairman in April (see "As Vertex Broadens Remit, Leiden Handing Baton to Kewalramani")...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Vertex Pharmaceuticals Inc.